OS Therapies (OSTX) Stock: Buy, Sell, or Hold?
OSTX - OS Therapies Incorporated
$1.68
-0.14 (-7.69%)
âŧ
5d:
-7.69%
30d:
+4.35%
90d:
-1.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 17, 2026
0d
Get Alerted When OSTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OSTX is fairly priced but lacks strong directional signals. At 1.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OSTX is fairly priced but lacks strong directional signals. At 1.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.23
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OSTX is currently trading at $1.68, which is considered slightly high relative to its 30-day fair value range of $1.54 to $1.76. The stock's valuation (Forward PE: 4.8) is in line with its historical norms (4.6). At these levels, the market is pricing in 1.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OSTX is in a uptrend. Immediate support is located at $1.60, while resistance sits at $2.02. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: OSTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.50 (+406.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OSTX is in a uptrend. Immediate support is located at $1.60, while resistance sits at $2.02. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: OSTX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.50 (+406.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.54 -
$1.76
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
39.0%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.7%)
- BULLISH: Trading 406.0% below Wall St target ($8.50)
- NEUTRAL: Market pricing in 1.4% annual earnings growth - fairly valued
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.54 -
$1.76
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$2.02
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.85
Wall Street Target
$8.50
(+406.0%)
Valuation Premium vs History
+1.4% premium
PE vs Historical
4.9 vs 4.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.4%
(market-implied from PE analysis)
1-Year Target
$1.70
(+1%)
2-Year Target
$1.73
(+3%)
3-Year Target
$1.75
(+4%)
3-Yr Target (if PE normalizes)
(PE: 5â5)
PE COMPRESSION
$1.66
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: September 13, 2026 8:14 PM ET
Data refreshes hourly during market hours. Next update: 9:14 PM
Data refreshes hourly during market hours. Next update: 9:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OSTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
